Russ Swan, Editor, writes:
We see from your search that you're looking for information on the term "RNAI",
and we have a large number of manufacturers' news releases and technical articles here on Laboratorytalk which will be of interest.
Let me be your guide.
Start with
the news release Oxford Biomedica buys RNA interference technology from
Oxford BioMedica, which we summarised at the time by saying "The rights granted are exclusive for RNAi gene silencing using lentiviral vector technology for human gene therapy applications, including Oxford BioMedica's proprietary LentiVector
system".
Earlier in the week,
we featured the news release Rapid purification and enrichment of miRNA from
Sigma-Aldrich: "MirPremier microRNA isolation kit provides researchers tool for 50% faster miRNA preparation with no detectable large RNA and further supports Sigma's commitment to the rapidly developing area of RNAi".
In November 2007, we covered the news from Applied Biosystems
concerning its Silencer Select siRNAs
- take a look at Biomedical research siRNAs line expanded
which says: "Silencer Select siRNAs were developed to give the most consistent gene silencing and gene function data available to biomedical researchers performing ribonucleic acid interference (RNAi) experiments".
Take a look also at the news release from Agilent Technologies Europe, Library standardises on Agilent barcode technology,
as well as Proximity ligation for protein quantitation in PCR from Applied Biosystems,
and Proteomics profiling of RNAi in human cells from Cenix Bioscience.
See also:
Sequence disclosure for guaranteed gene knockdown
(August 2007)
Qiagen, the first company to provide sequences of predesigned siRNA products, says that its HP validated siRNAs will also be provided with full sequence information at no extra cost
IN Cell Investigator software tracks live cells
(August 2007)
GE Healthcare has released its new IN Cell Investigator software for high content analysis and screening
Small RNA testing carried out in vivo
(July 2007)
BIOO Scientific offers a variety of services using a number of different RNAi technologies including synthetic siRNA and vector-based approaches to help facilitate the progress of drug development
High-throughput tool for primary cell transfection
(July 2007)
The devices developed using Amaxa's Nucleofector technology will be the world's first technology enabling high-throughput screenings in efficiently transfected and differentiated primary cells
Novel in vivo RNAi services for gene function
(June 2007)
One of the Elisa detection kit is for mouse tumour necrosis factor (TNF) in serum, plasma, and cell culture supernatant is a potent mediator of immune and inflammatory responses
Focus on the protein kinase family of drug targets
(June 2007)
Kinase Sarfari enables users to design compounds and focused libraries against specific protein kinases and rapidly optimise compound discovery through exploration of structure-activity relationships
Custom RNA interference service launched
(June 2007)
Bioo Scientific is launching a service to perform in vivo RNAi testing to facilitate progress in the drug pipeline (target identification, characterisation and drug development)
Pharmaceutical lab conference stream at LAB
(March 2007)
Lab UK, a new European trade fair and conference devoted to analysis, bio and laboratory equipment, announces the first in a series of conference streams to take place at the new exhibition in London
Automated assay-ready cell culture
(January 2007)
Thermo Fisher Scientific unveils its new cell growth and discovery (CGD) WorkCell, a fully enclosed, environmentally controlled system for high capacity cell growth, supply and in-line image analysis
World's first rat druggable genome siRNA Set V1.0
(January 2007)
This set enables potent and specific knockdown of ~6000 rat genes which correspond to human genes of potential therapeutic value
Cequent to evaluate Cobra ORT Technology for RNAi
(January 2007)
Cobra Biomanufacturing has signed an agreement with Cequent Pharmaceuticals to develop a treatment for an inherited form of bowel tumour (familial adenomatous polyposis, FAP)
New scientific online resources at ASCB Meeting
(December 2006)
Invitrogen introduced the newest member of its free online scientific resource collection, iGene, a platform that allows researchers to conveniently search for experimental reagents by gene or protein
News on the Optimizing Synthetic RNAi from Bioinformatics
(December 2006)
A new report from BioInformatics found that while the use of synthetic siRNA is still relatively new, the industrial market segment will continue strong growth over the near term
Millipore releases AdenoSilence vectors for RNAi
(December 2006)
Millipore has announced the launch of the first round of adenoviral shRNA expression vector reagents targeting the human druggable genome
Dublin joins RNAi programme
(November 2006)
Sigma-Aldrich welcomes Dublin City University to the RNAi Partnership programme
HP OnGuard siRNA design ensures successful RNAi
(October 2006)
SiRNA design is reinforced using the results from Qiagen's siRNA validation project in which thousands of siRNAs have been tested for effectiveness by real-time RT-PCR
RNAi screening of human druggable genes
(October 2006)
Qiagen says it has taken another step forward for RNAi screening of the human druggable genome with the launch of the human druggable genome siRNA set V3.0
Convergence of functional genomics and proteomics
(October 2006)
Cenix BioScience, Applied Biosystems, and the Biotechnology Centre (Biotec) of the Technische Universitat Dresden establish facility to pioneer the convergence of functional genomics and proteomics
Economical RNAi screening without compromises
(October 2006)
FlexiPlate siRNA allows creation of exactly the set of siRNAs needed without compromising on any requirements, enabling fully customised RNAi for pathway analysis or follow-up screening experiments
U of Edinburgh joins RNAi Partnership programme
(October 2006)
Sigma-Aldrich welcomes the University of Edinburgh to the RNAi Partnership programme, gaining access to functional genomics portfolio including TRC shRNA libraries
Distribution rights of RNA interference library
(September 2006)
CRT grants Geneservice a worldwide exclusive licence to distribute the pSuper RNAi vector system and pRetrosuper vector-based shRNA library generated at the Netherlands Cancer Institute (NKI)
The next generation of transfection reagents
(September 2006)
Lipofectamine LTX provides highly effective delivery of DNA into a wide range of cell types and a significantly lower toxicity profile
Calando selects Agilent for siRNA production
(August 2006)
Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, has selected Agilent Technologies to manufacture the active siRNA component in its lead RNAi product, Calaa01
Increased usage of key protein research techniques
(August 2006)
The utilisation of protein research techniques such as Elisa and Western blot by drug discovery researchers has increased from 45 to 59 percent and from 46 to 58 percent respectively from 2002 to 2006
Developing new SiRNA-based therapeutics
(August 2006)
Perbio Science reports that Abbott and Dharmacon has announced a collaboration to develop new therapeutic agents based on a gene silencing technology of RNA interference (RNAi)
SYBR GreenER qPCR reagent kits
(August 2006)
SYBR GreenER reagents produce much brighter fluorescence and less PCR reaction inhibition, thereby increasing the sensitivity of the qPCR assay
Lentviral shRNA gene family sets expanded
(July 2006)
Sigma-Aldrich, has announced the expansion of shRNA gene family sets in lentiviral format for direct use in gene silencing
Lentivector is the 'system of choice' for RNAI
(July 2006)
Paper in Nature Medicine demonstrates efficacy of Oxford BioMedica's LentiVector technology in an animal model of inherited (familial) amyotrophic lateral sclerosis (ALS) or motor neuron disease
Experimentally validated siRNA duplexes
(July 2006)
Bio-Rad Laboratories and Integrated DNA Technologies (IDT), have announced a collaborative agreement to develop RNA interference (RNAi) tool sets for life science researchers
Alliance for commercialisation of lentivector
(July 2006)
Oxford BioMedica and Sigma-Aldrich announced an agreement for Sigma-Aldrich to commercialise Oxford BioMedica's LentiVector technology for the reagent and research tool market
New members for RNAi Global
(July 2006)
VUMC, Amsterdam, Harvard and Stanford Medical schools join 12 international research centers and Dharmacon as members of RNAi Global initiative
Open Biosystems responds to lawsuit
(June 2006)
Open Biosystems responds to the lawsuit filed by Sigma-Aldrich and Oxford Biomedica alleging patent infringement, and reaffirms its commitment to the distribution of TRC lentiviral libraries
Lawsuit for infringement of key patents
(June 2006)
Sigma-Aldrich and Oxford Biomedica pursue protection of RNAi-related intellectual property file suit against Open Biosystems
Partnership for siRNA design with Rosetta
(May 2006)
Sigma-Aldrich has entered an arrangement with Rosetta Inpharmatics to access the company's proprietary and patent pending bioinformatics design tools for siRNA research and development purposes